CorMedix Inc - Stock Price History | CRMD

Historical daily share price chart and data for CorMedix Inc since 2021 adjusted for splits. The latest closing stock price for CorMedix Inc as of September 23, 2021 is 4.74.
  • The all-time high CorMedix Inc stock closing price was 49.35 on April 01, 2015.
  • The CorMedix Inc 52-week high stock price is 18.80, which is 296.6% above the current share price.
  • The CorMedix Inc 52-week low stock price is 4.36, which is 8% below the current share price.
  • The average CorMedix Inc stock price for the last 52 weeks is 7.78.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
CorMedix Inc Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 5.5274 7.0600 9.1500 2.3500 7.4300 2.06%
2019 7.8286 6.9500 13.2500 4.9600 7.2800 12.87%
2018 3.0757 2.6500 11.3000 0.8705 6.4500 156.97%
2017 4.4571 8.5500 12.0000 1.6750 2.5100 -67.19%
2016 11.1206 9.5000 22.5000 6.1500 7.6500 -24.63%
2015 21.1561 9.6000 49.3500 9.0500 10.1500 6.28%
2014 9.4204 6.8000 14.5000 6.5500 9.5500 54.03%
2013 4.2861 3.7500 6.2500 2.4500 6.2000 72.17%
2012 1.8122 1.2995 3.8500 0.8255 3.6010 155.03%
2011 6.2464 8.9500 11.1000 1.1005 1.4120 -84.48%
2010 8.7205 15.0000 15.2000 5.7000 9.1000 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.177B $0.000B
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Defencath (TM), a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. Defencath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product, which provides an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA. CorMedix also intends to develop Defencath as a catheter lock solution for use in oncology and total parenteral nutrition patients. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrog
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71